Radiofrequency catheter ablation (RFA) of the inferior vena cava–tricuspid isthmus is the treatment of choice for atrial flutter (AFL) given its high efficacy. One controlled study of AFL with medication has been done to date.\(^1\) Despite the introduction and high success rate of periblation, questions remained: is transisthmus ablation a definite cure for patients with AFL or can their follow-up be characterised by the occurrence of other atrial arrhythmia? Many studies, some recent, have tried to answer these questions\(^2\)–\(^3\) but one question remains: will first line transisthmus ablation alter the long term risk of atrial fibrillation (AF)? The aim of this study was to evaluate the long term risk of subsequent AF after RFA in two groups of patients < 80 years old with lone AFL: group 1, receiving first line RFA treatment; and group 2, receiving RFA after failure of at least one drug treatment after restoration of sinus rhythm. By convention, lone AFL excluded prior evidence of AF.

**PATIENTS AND METHODS**

Over 44 months, 318 patients were referred for RFA treatment for AFL (February 1998 to October 2001). Only 176 patients (55.3%) were enrolled. Inclusion criteria were as follows: typical AFL on the ECG; typical intracardiac electrogram activation sequence reported by analysis of the activation sequence with a dodecapolar catheter; evidence of isthmus participation during entrainment manoeuvres; and prior evidence of AF excluded by lone AFL. Exclusion criteria were a documented history of AF and age > 80 years old. Patients were enrolled in group 1 if the first episode of AFL was treated by RFA (first line treatment). Patients were enrolled in group 2 when RFA was applied after at least one documented recurrence after medication following sinus rhythm restoration. Secondary prevention relied on drug treatment. Of the 176 patients aged 63 (11) years (33 women) with lone AFL, 93 patients were in group 1 (64 (11) years) and 83 were in group 2 (61 (10) years). Of the initial 318 referred patients, 142 (44.7%) were excluded because of either age (25 patients) or a history of AF (117 patients). The procedural end point was defined as a complete bidirectional isthmus block.\(^4\) Cumulative risk of AF was determined by outpatient follow up, on recurring symptoms or palpitations, and at the end of the study (December 2002). The mean follow up was evaluated by the log rank test and Kaplan-Meier method. The data are presented as mean (SD).

**RESULTS**

Clinical presentation and electrophysiological data were as follows: age 63 (11) years; sex 18.75% women; AFL duration since onset 13 (23) months, structural heart disease 45.5%, left ventricular ejection fraction 58.6 (12%), and left atrial size 42 (7) mm. The mean duration of radiofrequency applications (minutes) was 14.6 (17) (range 1.5–120). A bidirectional isthmus conduction block was obtained in 171 of 176 patients (97.2%) and an incomplete block in five patients (2.8%). One local complication due to an accidental arterial puncture was noted (groin haematoma requiring surgical treatment; group 2). An AFL recurrence was documented in 11 of 170 (6.5%) patients. Of the initial 318 referred patients undergoing RFA for AFL, long term follow up was obtained for 170 (96.6%). Six patients were lost to follow up, three in group 1 and three in group 2 (not significant). During the outcome, 33 atrial arrhythmic

**Table 1** Comparison between group 1 and group 2

<table>
<thead>
<tr>
<th></th>
<th>Group 1 (n = 93)</th>
<th>Group 2 (n = 83)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>64 (11)</td>
<td>61 (10)</td>
<td>NS</td>
</tr>
<tr>
<td>Structural heart disease</td>
<td>49.5%</td>
<td>41%</td>
<td>NS</td>
</tr>
<tr>
<td>Left ventricular ejection fraction (%)</td>
<td>57 (12)</td>
<td>60 (11)</td>
<td>NS</td>
</tr>
<tr>
<td>Left atrial size (mm)</td>
<td>43 (7)</td>
<td>40 (6)</td>
<td>NS</td>
</tr>
<tr>
<td>AFL duration since onset (months)</td>
<td>1.6 (1.4)</td>
<td>27 (29)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Bidirectional block</td>
<td>97.8%</td>
<td>96.25%</td>
<td>NS</td>
</tr>
<tr>
<td>Duration of RFA application (minutes)</td>
<td>13.7 (14)</td>
<td>15.8 (19)</td>
<td>NS</td>
</tr>
<tr>
<td>Antiarrhythmic agents at end of follow up</td>
<td>23/90</td>
<td>23/80</td>
<td>NS</td>
</tr>
<tr>
<td>Mean follow up (months)</td>
<td>22 (12)</td>
<td>25 (15)</td>
<td>0.1</td>
</tr>
<tr>
<td>Overall atrial arrhythmias</td>
<td>24.4% (22/90)</td>
<td>27.5% (22/80)</td>
<td>NS</td>
</tr>
<tr>
<td>AFL recurrence</td>
<td>6.7% (6/90)</td>
<td>6.25% (5/80)</td>
<td>NS</td>
</tr>
<tr>
<td>Atrial tachycardia</td>
<td>4.4% (4/90)</td>
<td>3.75% (3/80)</td>
<td>NS</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>13.3% (12/90)</td>
<td>17.5% (14/80)</td>
<td>0.9</td>
</tr>
</tbody>
</table>

Abbreviations: AF, atrial fibrillation; AFL, atrial flutter; RFA, radiofrequency catheter ablation.
events occurred: AF in 26 of 170 patients (15.3%) and atrial tachycardia in seven of 170 patients (4.1%). Table 1 compares characteristics and treatment of group 1 and group 2.

DISCUSSION

The risk of AF following RFA for typical AFL has been appreciated for some time. The risk factors for recurrence have been identified as atypical flutter or a history of AF before ablation, abnormal left ventricular ejection fraction, and inducible AF. Without these factors, the risk of AF is believed to be relatively low. The question remained whether first-line transmural ablation would alter the long term risk of AF. Our study addressed this question and showed that despite a high periablation success rate of transmural catheter ablation, first line RFA of lone AFL does not alter the long term risk of subsequent AF. Some controversies exist regarding the risk of AF in patients without a history of AF (lone AFL). Results underlined a low risk with a prevalence close to 10% after mid term follow up. In a report from the Cleveland Clinic, however, the long term risk of AF after cavo-tricuspid isthmus RFA of AFL in patients with no history of AF was actually found to be quite high (77%). The mean follow up in that study was 36 (15) months, longer than in any previously reported studies. A retrospective study concerning medically treated AFL determined a 48% risk of AF within 10 years. That study found several variables associated with AF risk: sex (women being at a higher risk), age, hypertension, diabetes, and recurrent AFL. Only diabetes and recurrent AFL were independent predictors of AF. To that point, it was unknown whether first line RFA altered the long term risk of AF. Our study determined that first line RFA treatment of lone AFL does not reduce the long term risk of subsequent AF in patients with lone AFL. The prevalence of AF after ablated AFL in patients with lone AFL was found to be close to 15% after two years.

Authors’ affiliations

A Da Costa, C Romeyer-Bouchard, N Zarqane-Sliman, M Messier, B Samuel, A Kihel, E Faure, K Isaac, Division of Cardiology, University Jean Monnet, Saint-Etienne, France


Correspondence to: Dr Da Costa, Service de Cardiologie, Hôpital Nord, Centre Hospitalier Universitaire de Saint-Etienne, 42 055 Saint-Etienne Cedex 2, France; da.costa@uhs-forel.fr

Accepted 2 April 2004

REFERENCES

Impact of first line radiofrequency ablation in patients with lone atrial flutter on the long term risk of subsequent atrial fibrillation

A Da Costa, C Romeyer-Bouchard, N Zarqane-Sliman, M Messier, B Samuel, A Kihel, E Faure and K Isaaz

*Heart* 2005 91: 97-98
doi: 10.1136/hrt.2003.033308

Updated information and services can be found at:
http://heart.bmj.com/content/91/1/97

These include:

References

This article cites 5 articles, 2 of which you can access for free at:
http://heart.bmj.com/content/91/1/97#BIBL

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

- Drugs: cardiovascular system (8842)
- Clinical diagnostic tests (4779)
- Tachyarrhythmias (208)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/